Compositions and methods of use of targeting peptides...

Details Compositions and methods of use of targeting peptides... Compositions and methods of use of targeting peptides...

2011-05-31

2011-05-31

Li, Bao (Department: 1648)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

C530S300000

Reexamination Certificate

active

07951362

ABSTRACT:
The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity. An exemplary placental receptor is FcRn/β2M, and compounds that bind to FcRn/β2M are potential teratogens.

REFERENCES:
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4912040 (1990-03-01), Kaufman et al.
patent: 4931053 (1990-06-01), L'Esperance
patent: 5021236 (1991-06-01), Gries et al.
patent: 5081034 (1992-01-01), Bevilacqua et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5188964 (1993-02-01), McGuire et al.
patent: 5206347 (1993-04-01), Ruoslahti et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5259380 (1993-11-01), Mendes et al.
patent: 5270163 (1993-12-01), Gold et al.
patent: 5288846 (1994-02-01), Quertermous et al.
patent: 5304640 (1994-04-01), Asky et al.
patent: 5415874 (1995-05-01), Bender et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5453362 (1995-09-01), Lamarco et al.
patent: 5463026 (1995-10-01), Nakamura et al.
patent: 5464436 (1995-11-01), Smith
patent: 5492807 (1996-02-01), Santi
patent: 5506126 (1996-04-01), Seed et al.
patent: 5536814 (1996-07-01), Ruoslahti et al.
patent: 5585277 (1996-12-01), Bowie et al.
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 5670312 (1997-09-01), Santi
patent: 5688692 (1997-11-01), Jat et al.
patent: 5688935 (1997-11-01), Stephens et al.
patent: 5705610 (1998-01-01), Zuckerman et al.
patent: 5750344 (1998-05-01), Doyle
patent: 5840841 (1998-11-01), Zuckermann et al.
patent: 5866759 (1999-02-01), Jat et al.
patent: 5902598 (1999-05-01), Chen et al.
patent: 5955572 (1999-09-01), Ruoslahti et al.
patent: 6057098 (2000-05-01), Buechler et al.
patent: 6068829 (2000-05-01), Ruoslahti et al.
patent: 6174861 (2001-01-01), O'Reilly et al.
patent: 6184973 (2001-02-01), Baer et al.
patent: 6215550 (2001-04-01), Baer et al.
patent: 6232440 (2001-05-01), Hillman et al.
patent: 6271196 (2001-08-01), O'Brien
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6350855 (2002-02-01), Tobin
patent: 6399384 (2002-06-01), Jat
patent: 6458381 (2002-10-01), Sourovoi et al.
patent: 6528281 (2003-03-01), Tobin
patent: 6576239 (2003-06-01), Ruoslahti et al.
patent: 6881825 (2005-04-01), Robbins et al.
patent: 2001/0046498 (2001-11-01), Ruoslahti et al.
patent: 2003/0113320 (2003-06-01), Ruoslahti et al.
patent: 2005/0191294 (2005-09-01), Arap et al.
patent: 19605175 (1997-08-01), None
patent: 0639584 (1998-04-01), None
patent: 4026631 (1992-01-01), None
patent: WO 92/00091 (1992-01-01), None
patent: WO 92/03461 (1992-03-01), None
patent: WO 92/06191 (1992-04-01), None
patent: WO 94/28424 (1994-12-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO 96/34874 (1996-11-01), None
patent: WO 96/34875 (1996-11-01), None
patent: WO 97/10507 (1997-03-01), None
patent: WO 97/19954 (1997-05-01), None
patent: WO 97/39021 (1997-10-01), None
patent: WO 98/10795 (1998-03-01), None
patent: WO 98/39469 (1998-09-01), None
patent: WO 99/04813 (1999-02-01), None
patent: WO 97/30024 (1999-09-01), None
patent: WO 99/46284 (1999-09-01), None
patent: WO 99/57311 (1999-11-01), None
patent: WO 00/14215 (2000-03-01), None
patent: WO 01/13114 (2001-02-01), None
patent: WO 01/42276 (2001-06-01), None
patent: WO 01/53342 (2001-07-01), None
patent: WO 02/02055 (2002-01-01), None
patent: WO 02/20722 (2002-03-01), None
patent: WO 02/20723 (2002-03-01), None
patent: WO 02/20769 (2002-03-01), None
patent: WO 02/20822 (2002-03-01), None
patent: WO 03/022991 (2003-03-01), None
Wu et al. J. Virology 2006, vol. 80, No. 22, pp. 11393-11397.
Miki et al. J. Biolog. Chemist. 1999, vol. 274, No. 41, pp. 29057-29062.
Pan et al. J. Protein Chem., 1999, 18(5): 579-584.
O'Brien Immunone Research 2008, p. 1-7.
Deshayes et al. Biochemistry 2004, vol. 43, pp. 7698-7706, see p. 7705.
Aiello et al., “Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins,”Proc. Natl. Acad. Sci., USA, 92(23):10457-10461, 1995.
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,”N. Eng. J. Med.,331(22):1480-1487, 1994.
Alliot et al., “Brain parenchyma vessels and the angiotensin system,”Brain Res.,830:101-112, 1999.
Alliot et al., “Pericytes and periendothelial cells of brain parenchyma vessels co-express aminopeptidase N, aminopeptidase A, and nestin,”J. Neurosci. Res.,58:367-378, 1999.
Alon et al., “Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity,”Nat. Med.,1:1024-1028, 1995.
Alonso and Maroto, “Plants as ‘chemical factories’ for the production of polyunsaturated fatty acids,”Biotechnology Advances,18:481-497, 2000.
Andrade et al., “Angiotensin-II-induced angiogenesis in sponge implants in mice,”Int. J. Microcirc. Clin. Exp.,16(6):302-307, 1996.
Arap et al., Steps toward mapping the human vasculature by phage display,Nature Med.,8(2):121-127, 2002.
Arap et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model,”Science, 279:377-380, 1998.
Arap et al., “Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands,”Cancer Cell, 6:275-284, 2004.
Arap et al., “Chemotherapy targeted to tumor vasculature ,”Curr. Opin. Onclol.,10(6):560-565, 1998.
Arap et al., “Targeting the prostate for destruction through a vascular address,”Proc. Natl. Acad. Sci., USA, 99:1527-1531, 2002.
Arden, “The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment.,”Br. J. Ophthalmol.,85:366-370, 2001.
Asako et al., “Organic solvent tolerance and antibiotic resistance increased by overexpression of marA inEscherichia coli,” Applied Environmental Microbiology, 63(4):1428-1433, 1997.
Assmann et al., “A nephritogenic rat monoclonal antibody to mouse aminopeptidase A. Induction of massive albuminuria after a single intravenous injection,”J. Exp. Med.,175:623-635, 1992.
Atkins et al., “Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation,”Bone, 26(6):653-661, 2000.
Baillie et al., “Tumor vasculature-A potential therapeutic target,”British J. Cancer, 72:257-267, 1995.
Baringa, “Peptide-guided cancer drugs show promise in mice,”Science, 279:323-324, 1998.
Baumann et al., “Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells,”J. Immunol.,157(1):284-290, 1996.
Beckman et al., “Experimental manipulation of the rodent visceral yolk sac,”Teratology,41(4):395-404, 1990.
Behm et al., “Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;13) and MLL

Affiliated with

Also associated with

Rating

Compositions and methods of use of targeting peptides... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods of use of targeting peptides..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods of use of targeting peptides... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2662995